Aurinia Pharmaceuticals: FDA Approved LUPKYNIS for Active Lupus Nephritis in Adults  

Aurinia Pharmaceuticals LUPKYNIS Approved for LN in Adults
Aurinia Pharmaceuticals (AUPH) has been granted a U.S. FDA approval of its product LUPKYNIS™ (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN).
Lupus Nephritis
LN is a serious progression of systemic lupus erythematosus (SLE) - a chronic, complex and . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.